Michigan Medicine Site Profile
aerial view of the U-M medical campus

Learn how Michigan Medicine can help you successfully execute your clinical trial or study. 

Michigan Medicine Overview

Michigan Medicine is a premier academic medical center made up of three hospitals with 60 subspecialties and more than 125 clinics throughout Michigan. In 2022-2023, Michigan Medicine was named number 1 in Michigan. Michigan Medicine is a national research leader based on many measures, such as the scope and quality of its investigations and the size of its research portfolio.

We are committed to improving clinical care, value, and health outcomes by successfully executing a diverse portfolio of high-quality clinical trials. To that end, Michigan Medicine created an organizational structure to better support the conduct of clinical trials, including a central Clinical Trials Support Office (CTSO) and Clinical Trial Support Units (CTSUs) that provide robust infrastructure, training, and oversight for studies performed at U-M.

Learn more about the Clinical Trials Support Units. 

By The Numbers
Fiscal Year 22
Number of Active Awards
Sponsored Awards
Sponsored Expenditures
Faculty FTEs (3,423) Headcount
Total Employees (Full Time)
Average Number of Licensed Beds
Diagnostic Imaging Procedures
Outpatient Clinic Visits, Treatments, Procedures
Active Clinical Trials
New Clinical Trials
Computer & Internet

External users are required to use their unique credentials, and when working remotely, access the network through the secure Virtual Private Network (VPN).

Unique user IDs are used to access the Electronic Medical Record (EMR) with an appropriate role assigned. This allows view access to a limited number of records for a limited time period.

Yes, the Clinical Research Associates (CRA/Monitor) are permitted access to the internet through wireless networks.

MWireless is the preferred network for employees for internet access and two-factor, Duo web login authentication is required.

Yes, the Clinical Research Associates (CRA/Monitor) will be able to access the EMR through our Michigan Medicine provider portal.

Yes, formal awareness training is required for all employees, contractors, sponsors, and other parties. There are documented disciplinary policies for violations of privacy or security of protected health information (PHI) or other sensitive data.

Yes, including who performed the access, what was accessed, and when the access occurred.

Information on CD-ROM access can be provided by the CTSU. Only FIPS 140-2 Michigan Medicine-approved removable media can be used.

Michigan Medicine recommends that shared files are authorized through the use of MiShare. MiShare is a secure collaborative file transfer system that provides a method approved by the Michigan Medicine Compliance Office for Michigan Medicine personnel, non-Michigan Medicine business partners, patients, and researchers to securely transfer files, including files that contain electronic Protected Health Information (ePHI), protected research data, or other sensitive information. Files are encrypted while being uploaded or downloaded and are encrypted while they are on the MiShare server. Dropbox is also an approved platform for ePHI.

Yes, it is the policy of Michigan Medicine to ensure the confidentiality, integrity, and protection of all sensitive data, including ePHI. Security assessments are conducted by the office of the Chief Security Officer and research systems containing ePHI are required to have IRB approval, a risk assessment, and authorization to operate.

Yes, we operate our Epic EMR system in line with federal, state, and local regulations, including the application of the NIST 800-53 family of controls. Epic is considered 21 CFR Part 11 compliant for electronic records and signatures.

Yes, underlying information systems supporting clinical trials management are set up in the Michigan Medicine infrastructure to meet institutional information assurance and security requirements.

Yes, underlying information systems supporting clinical trials management have change control processes in place to test, approve and document changes.

Yes, in order to use information systems, users are required to have a unique ID managed by an Identity and Access Management team.

Systems are regularly maintained along their lifecycle from design, implementation, and operation to retirement.

Budget & Contracts

The University of Michigan Office of Research and Sponsored Projects (ORSP) enables and safeguards the conduct of research and other sponsored activities for U-M. ORSP is responsible for activities such as contract negotiations of terms and conditions and facilitating the award as part of the U-M Office of Research. A second unit, the Office of Sponsored Programs, primarily oversees financial accounting to ensure compliance with applicable laws and sponsor regulations, such as allowed expenses and sponsor payment activities as part of U-M Business & Finance. The CTSUs closely partner with ORSP and Sponsored Programs on pre- and post-award activities.

No, the budget, other contract terms, and IRB can be developed and approved in parallel.

Once the protocol, budget, and contract are made available and approved through the CTSU feasibility process, the general contract terms will be sent to ORSP for review. In parallel the CTSU finance team will review the budget with the study team and lead any budget negotiations. Once the budget is finalized, it will route for internal approvals to ORSP to incorporate with the final contract language. The full contract will be processed for signatures once the budget has been routed internally for approvals and contract terms are negotiated. The turnaround time for final signature (once the Principal Investigator has signed) is typically less than three business days; however, any sponsor requirement of original ink signatures will likely prolong the signature process.

The Clinical Trials Support Units (CTSUs) are responsible for developing a study budget and working collaboratively with the Principal Investigator and their academic department to negotiate a final budget with the sponsor. The CTSUs will submit the final budget to the University of Michigan Office of Research and Sponsored Projects to include in the study agreement along with negotiated payment terms

In special circumstances the CTSUs will assist U-M investigators in estimating the cost of conducting a trial at Michigan Medicine based on a draft protocol. However, a final protocol, draft contract, and budget template are required for feasibility review. Once approved, the contract and budget review process will begin.


Each CTSU or program can provide the budget specialist information upon request, or for general inquiries, please contact the Clinical Trials Support Office.

Payment Information

To ensure proper processing of your payment, regardless of the payment method, please notify the University of Michigan that a payment has been sent by sending an email to [email protected]

For sponsor remit payment and to ensure payment is applied correctly, include a Reference Number. 

Reference Numbers should use a University of Michigan-assigned identifying number (e.g., PAF Number, P/G (Project/Grant) Number, or AWD Number). Invoice payments should include the Invoice Number or Customer Number. 

For general communications regarding payment issues, contact [email protected].
Address: SSC Accounts Receivable, 1000 Victors Way Suite 1A, Ann Arbor, MI 48108-2744 
Phone: 734-615-2000 
Fax: 734-763-7086 

Credit card payments are not accepted. 

The Regents of the University of Michigan EFT Depository Account
[provide reference number as described above]
Checking Account Number: 5401125777
ABA/Routing number: 071000039

Bank Name and Address:
Bank of America
4805 Towne Centre Road, Suite 200
Saginaw, MI 48604

The Regents of the University of Michigan EFT Depository Account
[provide reference number as described above]
Checking Account Number: 5401125777
ABA/Routing number: 026009593 (from inside USA)
Swift Code: BOFAUS3N (from outside USA)

Bank Name and Address:
Bank of America
4805 Towne Centre Road, Suite 200
Saginaw, MI 48604

The Regents of the University of Michigan
Check Memo: [provide reference number as described above]
Mailing Address:
℅ BNY Mellon
Box 223131
Pittsburgh, PA 15251-2131

U-M will also accept payments via Bill.com. If the sponsor requests information, provide the following:

Account Email Address: [email protected]
Payment Network ID: 0138818634399219

Bill.com does not require invoicing (no need to contact SSC for an invoice), nor do we have to create a new account to provide this information. 

Tax ID Number: 38-6006309


Contracts are handled by the Office of Research and Sponsored Projects. Contact information for a contract specialist will be provided upon request.

Wolverine Tower, First Floor
3003 South State St.
Ann Arbor, MI 48109-1274

Yes, the Office of Research and Sponsored Projects (ORSP).

Yes, the CTSUs will assist with routing all draft CDAs to the Office of Research and Sponsored Projects for review and execution. 

When the investigator receives a CDA, they should work with their Clinical Trials Support Unit to submit the CDA to the Office of Research and Sponsored Projects for negotiation and execution.

The Investigators are not authorized to sign CDAs. Office of Research and Sponsored Projects will review and/or negotiate and sign.

Yes, we do have some MCDAs. If so, a submission to Office of Research and Sponsored Projects is required for institutional signature.

This varies. If an MCDA exists, it can be signed quickly. If not, CDAs are generally executed within 16 calendar days on average. The duration is impacted by the Sponsor and/or CRO responsiveness.

Michigan Medicine requires the following documents:

  • Protocol
  • Draft Contract
  • Draft Budget
  • Informed Consent
  • Investigator brochure
  • Study Manuals (Pharmacy, central lab, IVRS, etc.)
  • Subject material requiring IRB approval

Negotiation of Clinical Trial Agreements varies and can range from a few weeks to two months from the point a contract draft is available. University of Michigan supports and encourages the use of the Accelerated Clinical Trials Agreement (ACTA) to speed the negotiation process.

Each CTSU or department administrator will provide the contract specialist information as needed upon request.


Department Specific

Yes, Michigan Medicine has three internal EDCs that are utilized by study teams. These include REDCap (Research Electronic Data Capture), OpenClinica, and Velos eResearch. Details on these systems can be obtained here. Michigan Medicine study teams also have experience with numerous sponsor-specific EDC systems. Each CTSU can provide the list of EDC systems upon request.


OnCore Clinical Trials Management System:
All clinical trials being serviced by a CTSU are managed in OnCore, an enterprise Clinical Trials Management System. OnCore allows for automated standard interfaces with MiChart (EMR), which helps reduce duplicate data entry and integrates clinical research billing for increased efficiency and accuracy. OnCore provides complete subject and financial management for all clinical trials at Michigan Medicine. Learn more about OnCore.

Advarra eReg:
eReg is a compliant tool for managing all required regulatory documents for human subjects research. eReg integrates with the existing U-M OnCore CTMS, manages document owners and expiration dates, routes documents for signature or other notifications, and is 21 CFR Part 11 compliant for electronic signatures. eReg can share documents across multiple protocols and allows secure access for study sponsor monitoring. Learn more about eReg.

Calendar Review and Analysis Office (CRAO) assists principal investigators and study teams conducting clinical research to ensure all billable items and services align with payor and university policies. Clinical research billing analysts facilitate building the billing grid (calendar), reviewing required core documents for alignment with Medicare and university policies, resolving research participant billing issues, and auditing studies for compliance. Learn more about CRAO.

Contact Information

The CTSU Portfolio Managers can assist you with identifying a potential U-M investigator and navigating the U-M system. The contact information is provided below. For general assistance, contact the central Clinical Trial Support Office.

Each CTSU will provide the potential PI information, as needed.

Each CTSU will provide the study coordinator information, as needed.

Each CTSU will provide the finance administrator information, as needed.


Site visits can be arranged by appointment in partnership with the principal investigator or study team. 

Our site is an academic medical center.

Michigan Medicine comprises 20 clinical departments, including:

  • Anesthesiology
  • Cardiac Surgery
  • Dermatology
  • Emergency Medicine
  • Family Medicine
  • Internal Medicine:
    • Allergy and Clinical Immunology
    • Cardiovascular Medicine
    • Gastroenterology and Hepatology
    • General Medicine
    • Genetic Medicine
    • Geriatric and Palliative Medicine
    • Hematology and Oncology
    • Hospital Medicine
    • Infectious Diseases
    • Metabolism, Endocrinology & Diabetes
    • Nephrology
    • Pulmonary and Critical Care
    • Rheumatology
  • Neurology
  • Neurosurgery
  • Obstetrics/Gynecology
  • Ophthalmology & Visual Sciences
  • Orthopedic Surgery
  • Otolaryngology-Head and Neck Surgery
  • Pathology
  • Pediatrics:
    • Adolescent Medicine
    • Cardiology
    • Developmental-Behavioral Pediatrics
    • Critical Care Medicine
    • Endocrinology
    • Gastroenterology
    • General Pediatrics
    • Genetics, Metabolism & Genomic Medicine
    • Hematology/Oncology
    • Hospitalist Service
    • Infectious Diseases
    • Neonatal-Perinatal Medicine
    • Nephrology
    • Neurology
    • Psychology
    • Pulmonology
    • Rheumatology
  • Physical Medicine & Rehabilitation
  • Psychiatry
  • Radiation Oncology
  • Radiology
  • Surgery:
    • Cardiac Surgery
    • General Surgery
    • Oral & Maxillofacial
    • Pediatric Surgery
    • Plastic Surgery
    • Thoracic Surgery
    • Transplant Surgery
    • Vascular
  • Urology

Michigan Medicine provides two dedicated locations for the conduct of clinical research: Michigan Clinical Research Unit (MCRU) and Ravitz Cancer Center Research Unit (CCRU). Both facilities provide research-supported treatment beds, chairs, and trained research staff to ensure high-quality research-focused care. Clinical trials are also conducted in other adult or pediatric inpatient and outpatient facilities throughout Michigan Medicine.

Michigan Clinical Research Unit - Frankel Cardiovascular Center

  • 3 beds, 1 exam table, 4-recliner infusion bay suite
  • Staffed with 3 registered nurses and 4 medical assistants
  • Equipped with an ECG machine and vital sign monitoring devices
  • Emergency medical equipment, including a crash cart
  • Mobile study support

Ravitz Cancer Center Research Unit

  • 5 chairs and 1 bed
  • Staffed with 4 registered nurses and 3 medical assistant specialists
  • Infusion administration
  • Equipped with two ECG machines and a DASH 4000 vital sign monitoring device.
  • Emergency medical equipment, including crash cart

Capabilities at Both Locations

  • Timed blood draws
  • Urine and PK/PD sampling
  • Monitor space
  • Sample & storage of specimens
  • Oral investigational product administration, accountability, and compliance
  • Patient education regarding study medication and clinical trials
  • Patient visits on weekends
  • Language translators

All equipment is regularly calibrated and maintained to ensure accuracy and is in compliance with accrediting organizations. The list below represents equipment in the research units, however, studies have access to resources throughout Michigan Medicine.

  • Computerized Tomography Scan
  • Dual-Energy X-ray Absorptiometry or Bone Densitometry
  • Magnetic Resonance Imaging
  • Fluoroscopy
  • Positron Emission
  • Tomography Scan
  • X-Radiation
  • Mammography
  • Nuclear Medicine (e.g., bone scan, thyroid scan, thallium cardiac stress test)
  • Electrocardiogram
  • Refrigerated centrifuge
  • Centrifuge
  • Refrigeration, including equipment for storage of investigational products:
    • Refrigerator (2° to 8°C)
    • Freezer (-20° to -30°C)
    • Refrigerator (-70° to -80°C)
    • Refrigerator (Liquid Nitrogen -135°C)
    • Temperature monitoring by the minute, with logs maintained
    • Back-up power
    • Temperature alarm


Radiology and Other Testing





Yes. Multiple clinical laboratories are available. The Rogel Cancer Center, Michigan Clinical Research Unit (MCRU), and other independent program laboratories are available for research specimen processing, storage, and shipping. The Medical School Central Biorepository, a College of American Pathologists (CAP) accredited state-of-the-art facility, is also available for specimen storage, processing, and distribution services. There is also a sample processing lab at our Brighton offsite clinic.

Lab Locations

Michigan Clinical Research Unit Specimen Processing Lab
Frankel Cardiovascular Center
1425 East Ann Street
Ann Arbor, MI 48109

Clinical Research Specimen Processing Unit
Rogel Cancer Center
1500 East Medical Center Drive
Ann Arbor, MI 48109

North Campus Research Complex
2800 Plymouth Road, Bldg 35
Ann Arbor, MI 48109-2800
CLIA and CAP Certified

Central Biorepository
North Campus Research Complex
2800 Plymouth Road, Bldg 60
Ann Arbor, MI 48109-2800
CAP Accredited


Yes. A list of CAP accreditations can be obtained at Mlabs.

Yes, all Michigan Medicine Clinical Laboratories are CLIA-certified. Clinical research laboratories do not require CLIA certification. A list of CLIA certifications can be obtained at Mlabs.


  • College of American Pathologists (CAP)
  • Clinical Laboratory Improvement Act/Amendment (CLIA)
  • American Nurses Credentialing Center (Magnet)
  • FWA - 00004969
  • Laboratory International Air Transport Association for Hazardous Materials (HAZMAT & IATA)


Yes, the Local Normal Ranges (LNRs) can be found here.

Yes, through the Michigan Clinical Research Unit, Cancer Center, other independent program laboratories, offsite clinics, and the Medical School Central Biorepository, there are appropriate specimen storage freezers that are temperature alarmed and monitored.


U-M has an investigational pharmacy with a designated lead research pharmacist assigned to each study who is responsible for assuring protocol and regulatory compliance related to dispensing and management of the investigational drug. Learn more about Research Pharmacy.

Michigan Medicine Research Pharmacy
UH B2D301, Box 5008
1500 East Medical Center Drive
Ann Arbor, MI 48109-5008

Phone: 734.936.7469
Fax: 734.647.9302

Questions? Email: [email protected]

Yes, all investigational drugs are kept in dedicated pharmacy areas with limited access to pharmacy personnel only.

Yes, the storage areas are maintained according to USP standards for drug storage, and the environment is monitored using an automated electronic system, Temp Track.

Yes, for investigational drugs that the Research Pharmacy manages.



Yes — copies of all policies and SOPs are available upon request.

Yes. Study Teams can access research pharmacy services at offsite facilities such as Brighton, Northville, and Dominos Farms.

Yes. Investigational drugs being studied under an Investigational New Drug (IND) is eligible for interstate shipment without restriction. If a drug is not being studied under IND, but is shipped within Michigan, the drug may be eligible for shipment. Drugs not studied under IND cannot be shipped out of state.


2800 Plymouth Road, Bldg 520, Room 3214
Ann Arbor, MI 48109-2800
(734) 763-4768

Email: [email protected]

Yes, studies are conducted per sponsor requirements and follow ICH-GCP guidelines.


Yes, electronic and remote informed consent procedures are permitted by IRBMED and must meet the same regulatory and institutional requirements of an in-person paper-based informed consent process.

Yes, when U-M agrees to cede regulatory oversight to a commercial IRB. U-M currently has master agreements with several commercial IRBs. Ancillary committee review and approvals, and IRBMED acknowledgement to cede letter are required prior to commercial IRB review of site. 

IRBMED consists collectively of 6 Boards and hosts 3 Board meetings per week. The A1 and A2 Boards meet simultaneously every other Thursday, and the B1 and B2 Boards meet simultaneously on alternating Thursdays.  The C1 and C2 Oncology Boards meet on alternating Fridays.

Yes. U-M was reaccredited with Full Accreditation in 2021 for five years. U-M has held Full Accreditation
since 2008.

Certification, FWA:
FWA 00004969

To be considered for an upcoming Board agenda, all identified changes for an application must be addressed and resubmitted to IRBMED 8 business days in advance of the convened meeting.  Resubmission by this date does not guarantee that the application will be reviewed at the next convened meeting.

Time from review of a study at a full board meeting and notification of the outcome is typically within 2 business days.

Yes, if a need exists, access to the interpreter services is available upon request and appointment.


Yes, all new clinical trials in a CTSU will initially go through a feasibility review or a Cancer Center Protocol Review Committee (PRC) review. The reviews are conducted in partnership between the PI and CTSU.

The PRC meets on the 2nd and 4th Tuesday of each month with submissions due 1 week prior. For non-oncology studies, there are no deadlines for feasibility submission. Approval is typically received within 5 business days.

For regulatory review, the protocol is submitted through an electronic application system. The study will proceed to the applicable ancillary committees before the application reaches the IRB for review. U-M has several ancillary research review committees, including:

  • Calendar Review and Analysis Office
  • Conflict of Interest
  • Research Pharmacy
  • Radioactive Drug Research Committee
  • Subcommittee on Human Use of Radioisotopes
  • Institutional Biosafety Committee
  • Tissue Procurement Core

Studies are reviewed only by those review units that are applicable. Ancillary committee review and approval must be completed before final IRB approval is released.

Upon submission of the regulatory application, U-M’s electronic management system sends the IRB application to all applicable ancillary committees based on information provided in the application.

Meetings occur to meet the demands of the submitted studies.

Total time to approval will vary with an individual application’s review needs, including other committee reviews, application completeness and clarity at submission, and IRB reviewer schedules.

Participant Population

DataDirect: The Medical School Office of Research has developed a self-serve tool, DataDirect, for CTSUs and study teams to use to facilitate cohort discovery. DataDirect enables access to robust, up-to-date data on more than 2 million unique patients from across the health system to inform study design and determine availability of eligible patients for study recruitment.

UMHealthResearch.org is an engaged participant registry with over 60,000 users that enables the public to view active clinical and health research studies at U-M. This platform is provided by the Michigan Institute for Clinical & Health Research (MICHR), the home to U-M's NIH Clinical & Translational Science Award (CTSA).

The portal allows potential volunteers to search studies or be auto-matched based on self-reported health history and/or interests. Study teams can communicate with volunteers and send batched messages using editable templates. UMHR posts can be linked to social media ads to connect with thousands of MM patients using the Paid, Targeted Social Media Ad Service.

MiChart (EMR): The Best Practice Alerts (BPAs) can be developed in our EMR as recruitment or screening tools using potential participant identifiers associated with study eligibility, diagnosis codes, problem lists, appointment dates, attending physicians, and other variables.

EMERSE: The Electronic Medical Records Search Engine (EMERSE) works with free text clinical documents in the EMR to support rapid data retrieval.

The MICHR Participant Recruitment (PR) Program offers consultations to study teams across U-M and can assist with recruitment analysis and strategic planning that meet the needs of the study. The team works with investigators on recruitment plans that include retention strategies, development of effective recruitment materials, timelines, and community outreach.

The team offers assistance with the creation of Michigan Medicine and U-M branded recruitment materials such as brochures, posters, fliers and postcards to be distributed to potential volunteers. The PR Team can also meet with study teams to develop a robust social media campaign that includes demographic-targeted social media advertising to meet the enrollment goals set by the Principal Investigator

80% of patients reside within 50 miles of Michigan Medicine.

Adult - 77% Caucasian, 9% Black or African American, 5% Asian, 8% Other.

Pediatric - 73% Caucasian, 12% Black or African American, 6% Asian, 10% Other.

3% of Adults and 7% of Pediatrics patients identified as Hispanic/Latino.

Yes; 95% of adult and 97% of pediatric patients speak English as their first language. A small percentage speak Spanish, Japanese, Chinese, or Arabic. Interpreter services are available.

Study Teams

Yes, more information can be obtained once an investigator has been identified, including the investigator’s CV and the population that the investigator has access to.

U-M is well positioned with highly trained study personnel, including principal investigators, co-investigators, radiologists, pathologists, pharmacists, biostatisticians, project managers, study coordinators, registered nurses, LPNs, medical assistants specialists, research assistants, multisite coordinators, laboratory technicians, database developers, data managers, regulatory coordinators, study monitors, and recruitment consultants. Each department or program personnel may vary slightly.

The number of studies each coordinator works on depends on the requirements and complexity of the studies. Each CTSU works closely together to provide coverage to deliver shared study support.

Yes, more information can be obtained once an investigator has been identified. This information
will be provided by the CTSU.   

General Information



Yes. Click here for an extensive list of accreditations/certifications. 

Phase I thru Phase IV and post-marketing approval.

Michigan Medicine has several specialty and treatment centers, including the Rehabilitation Center, Kellogg Eye Center, Frankel Cardiovascular Center, and Geriatrics and Rehabilitation Centers. A complete list is available at: http://www.uofmhealth.org/our-locations/specialty-care-centers.

Cancer Care Centers: 
University of Michigan’s Rogel Cancer Center – All cancers represented

Children’s Hospital: 
C.S. Mott Children’s Hospital

Yes. U-M’s CTSA is housed in the Michigan Institute for Clinical & Health Research (MICHR).

Contact Us
Clinical Trials Support Office
Medical School Office of Research

M-CTSU: North Campus Research Complex, Building 520
O-CTSU: North Campus Research Complex, Building 300
2800 Plymouth Road
Ann Arbor, MI 48109

About Us

The Clinical Trials Support Office is a unit of the Medical School Office of Research, where our mission is to foster an environment of innovation and efficiency that serves the Michigan Medicine research community and supports biomedical science from insight to impact.